SRH AlsterResearch AG Update: Gerresheimer - Q1 results revenues in line; earnings better than expected

Gerresheimer AG (update)

Health Care
MCap EUR 2.7bn

BUY, PT EUR 107.00 (+26% potential)
Research_update

 

What’s it all about? For Q1 Gerresheimer reported revenues roughly in line with market expectations. Particularly, the cosmetics business remained impacted by the Corona pandemic. Earnings had suffered from a furnace expansion, still Gerresheimer topped profit expectations benefitting from the sale of a real estate in Germany. Ultimately, the
annual targets were confirmed. With a recovery in cosmetics, business development
should be in line with management's outlook and our expectations. We are reiterating
our target price of EUR 107.00 and our BUY rating

 

For 5 current investment ideas, check our Weekly Screener. This week we are looking for companies which have the highest upside to our / mean consenus price targets.

 

Please note that AlsterResearch publishes MiFID II compliant research only. For a detailed discussion on MiFID II, please visit https://www.research-hub.de